Healthy Adult ParticipantsNCT07388355
A Usability Study of a Multi-channel ECG Monitoring Device
A study testing eWave Patch in people with Healthy Adult Participants and Heart Disease, run by Wearlinq at 1 site in United States.
Trial summary
This study it to evaluate the usability of the WearLinq eWave patch in a general adult population. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Adult Participants, Heart Disease, Arrythmia
- What is being tested?
- eWave Patch
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 6 Jul 2026to 31 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult >18 years old and able to consent
- Capable of using a smartphone app
- Willing to shave patch area if needed
Who cannot join
- Planning to undergo an MRI during the study period
- Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies, or any other dermatological conditional that could confound placement or results
- Presence of pacemaker, ICD or other implanted electronic devices
- Open wounds, lesions or infected or inflamed areas of skin at the placement site (left-center of chest/sternum)
- Pregnant or intending to become pregnant during the course of the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Chris Daniel contact
United States1 site, 1 recruiting
- Recruiting
ABio Clinical Research Partners
New London, North Carolina, 28127
Andrea Brown, MS, 408-881-2611, wearlinqstudy@abioclinical.com
About this study
Official title: WearLinq eWave Patch Study
This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.
Read the detailed description
Once eligibility is determined, participants will receive and apply the WearLinq patch for 7 consecutive days (or until an endpoint is met). A subset of subjects will be asked to participate in an Extended Use Cohort (30 days).
- Conditions
- Healthy Adult Participants, Heart Disease, Arrythmia, Cardiac
- Being tested
- eWave Patch
- Keywords
- Electrocardiogram, ECG, EKG, Cardiac diagnostic
- Medical subject headings
- Heart Diseases, Arrhythmias, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
eWave PatchDevice
This device is a wearable multi-channel ECG monitoring device for continuous cardiac rhythm tracking.
| Study group | Role | What they receive |
|---|---|---|
| 7 Day Study | Experimental | Participants will receive and apply the WearLinq patch for 7 consecutive days Receives: Device: eWave Patch |
| Extended Use Cohort | Experimental | Participants will receive and apply the WearLinq patch for 30 consecutive days Receives: Device: eWave Patch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Wear Duration
Days of use until one of the following is reached: patch no longer adheres, signal loss, voluntary removal, or 7 days is achieved
Measured: 7 Days
Adverse Events
Incidences of self-reported adverse events for the duration of the study
Measured: 7 Days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start6 Jul 2026
- Primary completion31 Jul 2027 (estimated)
- Study completion31 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Adult ParticipantsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Wearlinq
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- ABio Clinical Research Partners
- Responsible party
- Sponsor
- Investigators
- Chris Daniel, Study director, WearLinq, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07388355
- Sponsor's protocol ID
- CLN 0001
- Status last verified
- Jul 2026
- First submitted
- 22 Jan 2026
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: No plans to be provided/Not applicable
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- WearLinq eWave Patch Study
- ClinicalTrials.gov ID
- NCT07388355
- Acronym / sponsor ID
- CLN 0001
- Conditions
- Healthy Adult Participants, Heart Disease, Arrythmia, Cardiac
- Keywords
- Electrocardiogram, ECG, EKG, Cardiac diagnostic
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- WearlinqIndustry (pharma, biotech, devices)
- Collaborators
- ABio Clinical Research Partners
- Study start
- 6 Jul 2026 (actual)
- Primary completion
- 31 Jul 2027 (estimated)
- Study completion
- 31 Jul 2027 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.
Detailed description
Once eligibility is determined, participants will receive and apply the WearLinq patch for 7 consecutive days (or until an endpoint is met). A subset of subjects will be asked to participate in an Extended Use Cohort (30 days).
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 7 Day Study | Experimental | Device: eWave PatchParticipants will receive and apply the WearLinq patch for 7 consecutive days |
| Extended Use Cohort | Experimental | Device: eWave PatchParticipants will receive and apply the WearLinq patch for 30 consecutive days |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adult >18 years old and able to consent
- Capable of using a smartphone app
- Willing to shave patch area if needed
Key exclusion criteria (5 listed)
- Planning to undergo an MRI during the study period
- Known allergic reaction to adhesives or hydrogels or with family history of adhesive skin allergies, or any other dermatological conditional that could confound placement or results
- Presence of pacemaker, ICD or other implanted electronic devices
- Open wounds, lesions or infected or inflamed areas of skin at the placement site (left-center of chest/sternum)
- Pregnant or intending to become pregnant during the course of the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| eWave PatchThis device is a wearable multi-channel ECG monitoring device for continuous cardiac rhythm tracking. | Device | 7 Day Study, Extended Use Cohort |
Primary outcome
Wear Duration
Time frame: 7 Days
Days of use until one of the following is reached: patch no longer adheres, signal loss, voluntary removal, or 7 days is achieved
Adverse Events
Time frame: 7 Days
Incidences of self-reported adverse events for the duration of the study
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Individual participant dataSharing planned: No. No plans to be provided/Not applicable
Related trials for Healthy Adult Participants
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
RecruitingPhase 1
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
Overweight and/or Obesity, Healthy Participants
RecruitingObservational study
Magnetic Field Maps With NV Application Kit MCG
Technical Feasibility and Performance of the Sensor System, Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chris Daniel contact
Chris Daniel study director
WearLinq, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing eWave Patch in people with Healthy Adult Participants and Heart Disease, run by Wearlinq at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andrea Brown, MS (408-881-2611, abrown@abioclinical.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Wear Duration (time frame: 7 Days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.